Pharma BD Deal Intelligence

Whitehawk Therapeutics, Inc. / Hangzhou DAC Biotech Co., Ltd.

2026 · Licensing/Option · Complete

Whitehawk Therapeutics entered a new option agreement with Hangzhou DAC for access to the CPT113 linker-payload technology for use in up to five additional ADC programs. Whitehawk will select targets and source antibodies while retaining global rights and full program control. Builds on Whitehawk's proprietary Carbon Bridge Cysteine Re-pairing (CBCR) bioconjugation platform.

Key facts

• Announced May 21, 2026
• Closed May 21, 2026
• Deal type Licensing/Option
• Therapeutic area oncology (solid tumors)
• Indications oncology (solid tumors)
• Key assets CPT113 linker-payload (for use in up to 5 ADC programs)
• Mechanism linker-payload technology platform (CPT113) for antibody-drug conjugates

← Browse all deals  ·  How we score deals